Aims

Surgeons have commonly used modular femoral heads and stems from different manufacturers, although this is not recommended by orthopaedic companies due to the different manufacturing processes.

We compared the rate of corrosion and rate of wear at the trunnion/head taper junction in two groups of retrieved hips; those with mixed manufacturers (MM) and those from the same manufacturer (SM).

We describe the application of a non-invasive extendible endoprosthetic replacement in skeletally-mature patients undergoing revision for failed joint replacement with resultant limb-length inequality after malignant or non-malignant disease. This prosthesis was developed for tumour surgery in skeletally-immature patients but has now been adapted for use in revision procedures to reconstruct the joint or facilitate an arthrodesis, replace bony defects and allow limb length to be restored gradually in the post-operative period.

We record the short-term results in nine patients who have had this procedure after multiple previous reconstructive operations. In six, the initial reconstruction had been performed with either allograft or endoprosthetic replacement for neoplastic disease and in three for non-neoplastic disease. The essential components of the prosthesis are a magnetic disc, a gearbox and a drive screw which allows painless lengthening of the prosthesis using the principle of electromagnetic induction. The mean age of the patients was 37 years (18 to 68) with a mean follow-up of 34 months (12 to 62). They had previously undergone a mean of six (2 to 14) open procedures on the affected limb before revision with the non-invasive extendible endoprosthesis.

The mean length gained was 56 mm (19 to 107) requiring a mean of nine (3 to 20) lengthening episodes performed in the outpatient department. There was one case of recurrent infection after revision of a previously infected implant and one fracture of the prosthesis after a fall. No amputations were performed. Planned exchange of the prosthesis was required in three patients after attainment of the maximum lengthening capacity of the implant. There was no failure of the lengthening mechanism. The Mean Musculoskeletal Tumour Society rating score was 22 of 30 available points (18 to 28).

The use of a non-invasive extendible endoprosthesis in this manner provided patients with good functional results and restoration of leg-length equality, without the need for multiple open lengthening procedures.

Growing prostheses have been utilised in the United Kingdom since the late 1970s. Various mechanisms have been tried, but to date all have required some form of surgical intervention. This has led to multiple hospital admissions and a large amount of resources, both in theatre time and rehabilitation. Over the last ten years the Department of Bio-Medical Engineering at University College, London, together with the Royal National Orthopaedic Hospital, Stanmore, have developed a prosthesis which does not require surgical intervention to elongate. The total cost of the development has been something in the order of £350,000.00. The design features are the power worm screw mechanism where one turn equals 1 mm of elongation, but attached to this mechanism is an epicyclic gearbox, which has been reduced in size so that it can fit in to the body of the prosthesis. The speed reduction achieved by the gear box is 13061 to 1. The mechanism is capable of withstanding an axial load of 1,350 newtons. When an external magnetic field is applied an external coil speed of 3,000 revs per minute leads to a lengthening of 0.23 mm per minute. To date the prosthesis has been inserted in three patients ages 11, 12 and 13. All were suffering from osteosarcoma of the distal femur and had previously received neo-adjuvant chemotherapy. Early elongation had been achieved in all patients without any major discomfort and without the need for either analgesia or inpatient admission. There had been no loss of range of movement in the early post-lengthening period.

This new prosthesis represents a significant advance in the management of skeletal sarcomas in children.